Importance of Pulmozyme
Pulmozyme plays an essential role in the cystic fibrosis (CF) treatment routine. Even when you can’t feel Pulmozyme working to fight CF, it is. Taking your Pulmozyme as prescribed is important because it can reduce your risk of lung infections requiring IV antibiotics.
Stacy Motenko knows all about the importance of sticking to a treatment routine. Just like you, Stacy finds that life can get very busy, but no matter how busy she is, she knows that staying on top of her treatments will help her better manage her CF.
In this video, Stacy will show you how she keeps up with her twice-daily Pulmozyme treatments, along with other daily medicines.
Keeping up with treatments can be hard, but every day matters.
You can do things to help make the prescribed treatment a little easier for you or your child.* During treatment you can:
The Cystic Fibrosis Foundation Guidelines recommend the use of Pulmozyme in CF patients. Ask your doctor for more information about Pulmozyme to see whether it is right for you.
* While clinical trial data are limited in pediatric patients younger than 5 years of age, the use of Pulmozyme should be considered for pediatric CF patients who may experience potential benefit in pulmonary function or who may be at risk of respiratory tract infection.
Pulmozyme (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.
In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.
Pulmozyme should not be used in patients who are allergic to any of its ingredients.
Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.
The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. While clinical trial data are limited in patients younger than 5 years of age, the use of Pulmozyme should be considered for pediatric CF patients who may experience potential benefit in lung function or who may be at risk of respiratory tract infection.
The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to <10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. Overall, the kind of side effects observed in children was similar to those seen in larger trials in older patients.
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
For further information, please see the full Pulmozyme Prescribing Information. If you have questions, please discuss them with your CF Care Team.